Trial Profile

Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Capecitabine (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

20 Jan 2024 Results(Between Feb 2022 and Jul 2023, n=14 pts) evaluating the efficacy and safety of camrelizumab (ICI targeting PD-1) combined with CCRT in the treatment of locally recurrent esophageal cancer presented at the 2024 Gastrointestinal Cancers Symposium
20 Jan 2022 Status changed from not yet recruiting to recruiting.
16 Jul 2021 Planned number of patients changed from 236 to 62.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com